Cargando…

RAD21 overexpression is frequently observed in BRCA-X Prostate Cancers

Detalles Bibliográficos
Autores principales:	Deb, S, Huiling, X, Thorne, H, Willems-Jones, A, Clouston, D, Bolton, D, Ramsay, R, Fox, SB
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327098/ http://dx.doi.org/10.1186/1897-4287-10-S2-A59

Ejemplares similares

Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers
por: Yan, Max, et al.
Publicado: (2012)

RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas
por: Deb, S, et al.
Publicado: (2014)

A multi-center study to evaluate the impact of germline BRCA1 and BRCA2 mutations on ovarian cancer survival
por: Bolton, KL, et al.
Publicado: (2012)

PIK3CA mutations are frequently observed in BRCAX but not BRCA2 -associated male breast cancer
por: Deb, Siddhartha, et al.
Publicado: (2013)

Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations
por: Gonzalez, R, et al.
Publicado: (1999)

Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors
por: Huang, Fei, et al.
Publicado: (2016)

The contribution of LARGE genomic rearrangements of BRCA1 and BRCA2 gene mutations in breast and ovarian cancer families in a clinical cohort
por: Sawyer, S, et al.
Publicado: (2012)

Rad21-Cohesin Haploinsufficiency Impedes DNA Repair and Enhances Gastrointestinal Radiosensitivity in Mice
por: Xu, Huiling, et al.
Publicado: (2010)

Contributions of the RAD51 N-terminal domain to BRCA2-RAD51 interaction
por: Subramanyam, Shyamal, et al.
Publicado: (2013)

Haplotype analysis in German families with recurrent BRCA1 and BRCA2 mutations
por: Wappenschmidt, B, et al.
Publicado: (2001)

RAD52 S346X variant reduces breast cancer risk in BRCA2 mutation carriers
por: Biswas, Kajal, et al.
Publicado: (2020)

Correction: Rad21-Cohesin Haploinsufficiency Impedes DNA Repair and Enhances Gastrointestinal Radiosensitivity in Mice
por: Xu, Huiling, et al.
Publicado: (2010)

Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
por: Phillips, KA, et al.
Publicado: (2012)

Non-Recombinogenic Functions of Rad51, BRCA2, and Rad52 in DNA Damage Tolerance
por: Prado, Félix
Publicado: (2021)

BRCA2 interacting proteins
por: Vidarsson, H, et al.
Publicado: (2000)

BRCA1 testing in Lithuania
por: Janavicius, Ramunas
Publicado: (2012)

Breast cancer in young women: prevalence of LOH at p53, BRCA1 and BRCA2
por: Johnson, SM, et al.
Publicado: (2000)

Selenium and the risk of cancer in BRCA1 carriers
por: Lubinski, J, et al.
Publicado: (2011)

Clinical Characteristics of Ovarian Cancer Classified by BRCA1, BRCA2, and RAD51C Status
por: Cunningham, J. M., et al.
Publicado: (2014)

Germline mutations of BRCA1-associated RING domain (BARD1) gene in breast and/or ovarian families negative for BRCA1 and 2 alterations
por: Ghimenti, C, et al.
Publicado: (2000)

Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland
por: Bielecka, Helena, et al.
Publicado: (2012)

Mutational analysis of BRCA1 and BRCA2 genes in Spanish women with early-onset breast cancer
por: Martínez-Ferrandis, JI, et al.
Publicado: (2000)

Estrogen receptor transcription and transactivation: Genetic modifiers of cancer risks conferred by BRCA1 and BRCA2
por: Devilee, P
Publicado: (2001)

Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland
por: Bielecka, Helena, et al.
Publicado: (2012)

Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer
por: Hamel, Nancy, et al.
Publicado: (2003)

Searching for BRCA3 by exome sequencing
por: Makunin, I, et al.
Publicado: (2012)

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
por: Byrski, T, et al.
Publicado: (2012)

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
por: Byrski, T, et al.
Publicado: (2012)

Risk factors associated with frequent infections in the elderly
por: Kowalski, Marek L, et al.
Publicado: (2015)

Vitamins A, E and D and cancer risk in BRCA1 carriers
por: Kąklewski, K, et al.
Publicado: (2012)

Yeast Rad52 is a homodecamer and possesses BRCA2-like bipartite Rad51 binding modes
por: Deveryshetty, Jaigeeth, et al.
Publicado: (2023)

When, how and why BRCA1 and BRCA2 genetic testing is offered to patients who do not meet standard criteria
por: Duffy, J, et al.
Publicado: (2012)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
por: Byrski, T, et al.
Publicado: (2011)

EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases
por: Cousineau, Isabelle, et al.
Publicado: (2011)

Prevalence of the most frequent BRCA1 mutations in Polish population
por: Brozek, Izabela, et al.
Publicado: (2011)

Molecular characterization of BRCA1 and BRCA2 genes in breast cancer patients under 40 years-old or with familiar cancer history
por: Millan, Silvia Vidal, et al.
Publicado: (2007)

BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial
por: Kote-Jarai, Z, et al.
Publicado: (2000)

Purified human BRCA2 stimulates RAD51-mediated recombination
por: Jensen, Ryan B., et al.
Publicado: (2010)

Genetic instability in the RAD51 and BRCA1 regions in breast cancer
por: Nowacka-Zawisza, Maria, et al.
Publicado: (2006)

Structural basis for stabilisation of the RAD51 nucleoprotein filament by BRCA2
por: Appleby, Robert, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mpknhf8760c7vofqbo61tovuqk